Spot the Theme: Biotechs and CLECs Rule the Calendar

With such a narrow focus in the queue this week, watching the deals trade is the only way to play.
Publish date:

This is my first column since I've been back, and I'm thrilled to be writing again! My vacation was an absolute blast. I'm rested, thinking clearly and ready to tell it like it is! It's amazing what a few days of room service and sunshine can do for a guy like me. Let's see if you can see a difference in my attitude.

In the meantime, the calendar is chock-o-block full of biotech and CLEC (competitive local exchange carrier) IPOs. You'll see what I mean when you get into the table. A week like this is great because you can just watch the deals stream by and


if the market likes the sector. This gives you almost real-time comps for the rest of the deals in the queue. Believe me, trading these things doesn't get any easier than this. Remember my March 12

piece where I suggested that you call



Adams Harkness

? Did you make the calls? If you didn't, you're gonna wish you had. That's all I'm going to say. Now go out and kill them!

Let's take a look at this week's offerings:

Ben Holmes is the founder of, a Boulder, Colo.-based research boutique (now a wholly owned subsidiary of specializing in the analysis of equity syndicate offerings. This column is not meant as investment advice; it is instead meant to provide insight into the methods of new and secondary offerings. Neither Holmes nor his firm has entered indications of interest in any of the companies discussed in this column. Holmes' This Week in IPOs column appears Sundays, This Week's Secondaries appears Tuesdays, Upcoming Lockup Expirations appears Wednesdays and The Quiet Period appears on Fridays. Under no circumstances does the information in this column represent a recommendation to buy or sell stocks. Holmes appreciates your feedback at